|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CDK8 |
Gene summary for CDK8 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CDK8 | Gene ID | 1024 |
| Gene name | cyclin dependent kinase 8 | |
| Gene Alias | IDDHBA | |
| Cytomap | 13q12.13 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | P49336 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1024 | CDK8 | CCI_1 | Human | Cervix | CC | 4.91e-08 | 6.75e-01 | 0.528 |
| 1024 | CDK8 | CCI_2 | Human | Cervix | CC | 1.26e-21 | 1.23e+00 | 0.5249 |
| 1024 | CDK8 | CCI_3 | Human | Cervix | CC | 1.97e-14 | 7.69e-01 | 0.516 |
| 1024 | CDK8 | HTA11_3410_2000001011 | Human | Colorectum | AD | 7.45e-20 | -6.71e-01 | 0.0155 |
| 1024 | CDK8 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.61e-08 | -5.75e-01 | -0.1808 |
| 1024 | CDK8 | HTA11_3361_2000001011 | Human | Colorectum | AD | 9.30e-07 | -6.33e-01 | -0.1207 |
| 1024 | CDK8 | HTA11_696_2000001011 | Human | Colorectum | AD | 9.48e-08 | -4.00e-01 | -0.1464 |
| 1024 | CDK8 | HTA11_866_2000001011 | Human | Colorectum | AD | 1.19e-04 | -3.72e-01 | -0.1001 |
| 1024 | CDK8 | HTA11_5212_2000001011 | Human | Colorectum | AD | 3.21e-04 | -7.25e-01 | -0.2061 |
| 1024 | CDK8 | HTA11_7862_2000001011 | Human | Colorectum | AD | 2.84e-02 | -5.90e-01 | -0.0179 |
| 1024 | CDK8 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.77e-11 | -6.02e-01 | 0.096 |
| 1024 | CDK8 | HTA11_10711_2000001011 | Human | Colorectum | AD | 7.80e-07 | -5.76e-01 | 0.0338 |
| 1024 | CDK8 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.70e-18 | -6.11e-01 | 0.0674 |
| 1024 | CDK8 | HTA11_6818_2000001021 | Human | Colorectum | AD | 7.87e-06 | -5.82e-01 | 0.0588 |
| 1024 | CDK8 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.48e-17 | -5.56e-01 | 0.294 |
| 1024 | CDK8 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 5.18e-03 | -5.70e-01 | 0.2585 |
| 1024 | CDK8 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 6.11e-13 | -5.17e-01 | 0.3005 |
| 1024 | CDK8 | A001-C-207 | Human | Colorectum | FAP | 1.68e-03 | -1.71e-01 | 0.1278 |
| 1024 | CDK8 | A015-C-203 | Human | Colorectum | FAP | 1.72e-34 | -5.76e-01 | -0.1294 |
| 1024 | CDK8 | A015-C-204 | Human | Colorectum | FAP | 2.35e-08 | -4.40e-01 | -0.0228 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CDK8 | SNV | Missense_Mutation | c.790N>A | p.Asp264Asn | p.D264N | P49336 | protein_coding | tolerated(0.13) | benign(0.073) | TCGA-D8-A1JN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozolum | SD | |
| CDK8 | insertion | Frame_Shift_Ins | novel | c.1052_1053insG | p.Ile351MetfsTer15 | p.I351Mfs*15 | P49336 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| CDK8 | insertion | Frame_Shift_Ins | novel | c.1053_1054insTTTCCAGTTAAGAGGCATT | p.Pro352PhefsTer20 | p.P352Ffs*20 | P49336 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| CDK8 | insertion | Frame_Shift_Ins | novel | c.983_984insATACAAAATTAGCTGGGCATGGT | p.Ala329TyrfsTer16 | p.A329Yfs*16 | P49336 | protein_coding | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| CDK8 | SNV | Missense_Mutation | c.968G>A | p.Arg323Gln | p.R323Q | P49336 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| CDK8 | SNV | Missense_Mutation | c.1378N>G | p.Gln460Glu | p.Q460E | P49336 | protein_coding | tolerated_low_confidence(0.08) | probably_damaging(0.953) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
| CDK8 | SNV | Missense_Mutation | c.1115N>G | p.Asn372Ser | p.N372S | P49336 | protein_coding | tolerated(0.81) | benign(0.001) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| CDK8 | SNV | Missense_Mutation | novel | c.515N>A | p.Ala172Asp | p.A172D | P49336 | protein_coding | deleterious(0) | probably_damaging(0.952) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| CDK8 | SNV | Missense_Mutation | c.1280N>T | p.Pro427Leu | p.P427L | P49336 | protein_coding | tolerated_low_confidence(0.08) | benign(0.285) | TCGA-CM-6675-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | fluorouracil | PD | |
| CDK8 | SNV | Missense_Mutation | novel | c.471N>G | p.Ile157Met | p.I157M | P49336 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1024 | CDK8 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR | ILORASERTIB | ILORASERTIB | ||
| 1024 | CDK8 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR | inhibitor | CHEMBL3544942 | RONICICLIB | |
| 1024 | CDK8 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR | inhibitor | 178102513 | PONATINIB | |
| 1024 | CDK8 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR | inhibitor | 363894179 | ||
| 1024 | CDK8 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR | inhibitor | 310264726 | ||
| 1024 | CDK8 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR | inhibitor | 363894181 | ||
| 1024 | CDK8 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR | AST-487 | AST-487 | ||
| 1024 | CDK8 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR | inhibitor | 375973251 | ||
| 1024 | CDK8 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR | Macrocycle derivative 14 | |||
| 1024 | CDK8 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR | inhibitor | 249565898 |
| Page: 1 2 3 4 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |